Other formats:
BibTeX
LaTeX
RIS
@article{2421698,
author = {Bešše, Andrej and Sedlaříková, Lenka and Buechler, Lorina and Kraus, Marianne and Yang, ChiehandHsiang and Strakova, Nicol and Soucek, Karel and Navrátil, Jiří and Svoboda, Marek and Welm, Alana L and Joerger, Markus and Driessen, Christoph and Bešše, Lenka},
article_location = {LONDON},
doi = {http://dx.doi.org/10.1038/s41416-024-02774-9},
keywords = {triple-negative breast cancer; HIV-protease inhibitors},
language = {eng},
issn = {0007-0920},
journal = {British journal of cancer},
title = {HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer},
url = {https://www.nature.com/articles/s41416-024-02774-9},
year = {2024}
}
TY - JOUR
ID - 2421698
AU - Bešše, Andrej - Sedlaříková, Lenka - Buechler, Lorina - Kraus, Marianne - Yang, Chieh-Hsiang - Strakova, Nicol - Soucek, Karel - Navrátil, Jiří - Svoboda, Marek - Welm, Alana L - Joerger, Markus - Driessen, Christoph - Bešše, Lenka
PY - 2024
TI - HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer
JF - British journal of cancer
PB - NATURE PUBLISHING GROUP
SN - 00070920
KW - triple-negative breast cancer
KW - HIV-protease inhibitors
UR - https://www.nature.com/articles/s41416-024-02774-9
N2 - BackgroundResistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations indicate that the efficacy of proteasome inhibitors in TNBC may be limited, suggesting the need for combination therapies.MethodsWe compared bortezomib and carfilzomib and their combinations with nelfinavir and lopinavir in TNBC cell lines and primary cells with regard to their cytotoxic activity, functional proteasome inhibition, and induction of the unfolded protein response (UPR). Furthermore, we evaluated the involvement of sXBP1, ABCB1, and ABCG2 in the cytotoxic activity of drug combinations.ResultsCarfilzomib, via proteasome beta 5 + beta 2 inhibition, is more cytotoxic in TNBC than bortezomib, which inhibits beta 5 + beta 1 proteasome subunits. The cytotoxicity of carfilzomib was significantly potentiated by nelfinavir or lopinavir. Carfilzomib with lopinavir induced endoplasmic reticulum stress and pro-apoptotic UPR through the accumulation of excess proteasomal substrate protein in TNBC in vitro. Moreover, lopinavir increased the intracellular availability of carfilzomib by inhibiting carfilzomib export from cells that express high levels and activity of ABCB1, but not ABCG2.ConclusionProteasome inhibition by carfilzomib combined with nelfinavir/lopinavir represents a potential treatment option for TNBC, warranting further investigation.
ER -
BEŠŠE, Andrej, Lenka SEDLAŘÍKOVÁ, Lorina BUECHLER, Marianne KRAUS, Chieh-Hsiang YANG, Nicol STRAKOVA, Karel SOUCEK, Jiří NAVRÁTIL, Marek SVOBODA, Alana L WELM, Markus JOERGER, Christoph DRIESSEN and Lenka BEŠŠE. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. \textit{British journal of cancer}. LONDON: NATURE PUBLISHING GROUP, 2024, 13 pp. ISSN~0007-0920. Available from: https://dx.doi.org/10.1038/s41416-024-02774-9.
|
